iBio Q1 2024 Earnings Report

iBio EPS Results

• Actual EPS: -$4.20
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

iBio Revenue Results

• Actual Revenue: $0.05 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

iBio Announcement Details

• Quarter: Q1 2024
• Date: 11/14/2023
• Time: N/A

iBio (NYSEAMERICAN:IBIO), a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.